header-logo
Radiation Oncology Banner

Kerns Laboratory

Location
MFRC 6009 (Lab)
MFRC 6010 (Office)

View principal investigator bio
Sara Kerns Laboratory
Kerns Lab research areas

Research Areas

The Kerns lab studies inherited genetic predisposition to development of late toxicities resulting from cancer treatment. Approaches include genome-wide association studies (GWAS), analysis of circulating biomarkers, and analysis of gene expression and epigenetic changes using biospecimens from patients undergoing treatment for cancer. The long-term goal of our research is to develop predictive models for use in the clinic to better personalize cancer treatment and survivorship care. Research conducted in the lab also aims to uncover novel biologic pathways that might be targeted to prevent or mitigate the toxic effects of cancer treatment. Much of this work is done collaboratively, through research consortia, to facilitate large-scale clinical genomic studies. Dr. Kerns is a leader in the NCI-supported International Radiogenomics Consortium and a member of the NIH-funded Polygenic Risk Methods in Diverse Populations (PRIMED) Consortium.

Current Members

headshot

Carson Gehl, BS

Data Specialist I

headshot

Sanchita Giri, MSc

Clinical Research Assistant II

sangiri@mcw.edu

headshot

Lauren Smith, BS

Data Specialist I

MCW Collaborators

headshot

William A. Hall, MD

Professor of Radiation Oncology and Surgery, School of Graduate Studies; Medical Director of Radiation Oncology, Froedtert & the Medical College of Wisconsin Clinical Cancer Center

Clinical and research interests include pancreatic cancer, prostate cancer, MRI guided radiation therapy, renal cell carcinoma and rectal cancer.

headshot

Paul Auer, PhD

Cancer Center Scholar; Director, Biostatistics Shared Resource, Cancer Center; Professor, Data Science Institute, Biostatistics

pauer@mcw.edu

headshot

Manzur Rahman Farazi, PhD

Statistical Research Scientist II, Biostatistics

mfarazi@mcw.edu

Kerns Laboratory Funding

Kerns Lab researcher
all
Current Funding
NIH/NCI R01CA291956
“Targeting angiotensin and inflammation to prevent radiotherapy-induced bladder toxicity”
(MPI: Marples, Kerns), 08/01/2024 – 07/31/2029

NIH/NCI R21CA280170
“The urinary microbiome and bladder toxicity after pelvic radiotherapy”
(MPI: Marples, Gill, Kerns), 08/01/2024 – 07/31/2026

NIH/NCI R01CA285801
“Multi-cohort validation of machine learning radiogenomic models (ML-RGx) to predict late toxicity in prostate cancer”
(MPI: Kerns, Hall, Oh), 07/01/2024 - 06/30/2029

NIH/NCI R01CA280115
“Clinical and pre-clinical investigation of extracellular vesicles as a mechanism of toxicity in the bladder of prostate cancer patients treated with radiotherapy”
(PI: Lee), 04/01/2024 – 03/31/2029
Completed Funding

NIH/NCI MP2PRT 22X016Q (subcontract to HHSN26100039)
“Evaluation of an inflammation polygenic risk score (iPRS) to predict cancer related cognitive impairment and fatigue in patients receiving chemotherapy for non-metastatic breast cancer in URCC0701 and URCC10055”
(PI: Kerns), 07/19/2022 – 12/31/2024

NIH/NCI UG1CA189961
“Biobank to Support Translational Research”
(MPIs: Janelsins, Kerns), 9/01/2021 – 8/31/2022

NIH/NCI K07CA187546
"Risk Prediction for Development of Adverse Effects Following Radiotherapy for Prostate Cancer”
(PI: Kerns), 9/18/2015 – 8/31/2021

Wilmot Cancer Institute’s Research Development Funding Program
“Elucidating the Role of the Renin-Angiotensin Pathway in Development of Hemorrhagic Radiation Cystitis”
(PIs: Kerns and Marples), 7/01/2020 – 6/30/2021

NIH/SBIR HHSN261201500043C
"Predictive Biomarkers of Adverse Reactions to Prostate Radiotherapy”
(PIs: Peterson-Roth, Kerns, Rosenstein), 9/1/2015 – 9/18/2020

DOD PC140371
"Genetic Modeling of Radiation Injury in Prostate Cancer Patients Treated With Radiotherapy”
(PIs: Rosenstein and Ostrer; UR site PI: Kerns), 9/1/2015 – 8/31/2018

Recent Publications